Browsing Tag
TScan Therapeutics Inc.
1 post
TScan launches Phase 3 ALLOHA-2 with $128m in cash and a looming funding gap
TSC-101 enters Phase 3 as TScan weighs promising donor-chimerism data against manufacturing complexity and a pre-readout funding gap.